Zinke Michael, Nageswaran Vanasa, Reinhardt Richard, Burmeister Thomas
Charité, Med. Klinik für Hämatologie, Onkologie, Tumorimmunologie, Hindenburgdamm 30, 12200, Berlin, Germany.
Max-Planck-Genomzentrum, Cologne, Germany.
Mol Diagn Ther. 2015 Oct;19(5):329-34. doi: 10.1007/s40291-015-0162-3.
The majority of patients with JAK2 V617F-negative essential thrombocythemia or primary myelofibrosis harbor mutations involving the calreticulin (CALR) gene. These mutations are located in CALR exon 9 and lead to a frameshift with subsequent alteration of the CALR protein C-terminus. They have emerged as valuable molecular markers for the diagnosis of clonal myeloproliferative diseases. Although a variety of CALR mutations have been described, two mutations, denoted type 1 and type 2, account for around 85 % of cases. The type 1 mutation encompasses a 52 bp deletion and the type 2 mutation a 5 bp TTGTC insertion.
This work describes the development and testing of quantitative real-time PCRs (qPCRs) for detecting these two mutations.
The final type 1 CALR qPCR displayed a sensitivity of <0.1 % mutant alleles and the type 2 CALR qPCR had a sensitivity of <0.01 % mutant alleles. Additionally, two new CALR mutations are reported.
These sensitive and specific qPCRs should be helpful in establishing the diagnosis and in monitoring minimal residual disease in patients during or after therapy.
大多数JAK2 V617F阴性的原发性血小板增多症或原发性骨髓纤维化患者存在涉及钙网蛋白(CALR)基因的突变。这些突变位于CALR第9外显子,导致移码,随后改变CALR蛋白的C末端。它们已成为诊断克隆性骨髓增殖性疾病的有价值的分子标志物。尽管已描述了多种CALR突变,但两种突变,即1型和2型,约占病例的85%。1型突变包括52bp的缺失,2型突变包括5bp的TTGTC插入。
本研究描述了用于检测这两种突变的定量实时PCR(qPCR)的开发和测试。
最终的1型CALR qPCR对突变等位基因的检测灵敏度<0.1%,2型CALR qPCR对突变等位基因的检测灵敏度<0.01%。此外,还报告了两种新的CALR突变。
这些灵敏且特异的qPCR有助于确诊以及监测患者治疗期间或治疗后的微小残留病。